Aravax appoints Financial Executive Thomas Ulmer to Board of Directors
November 1, 2020
Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, announced today the appointment of Thomas Ulmer to the Board of Directors. Mr. Ulmer was previously the Chief Financial Officer of Immatics N.V., a NASDAQ-listed biopharmaceutical company and brings nearly two decades of experience serving in financial leadership positions across small, medium and large size healthcare companies.
“With extensive global experience in our industry working with private and listed companies and diverse shareholder structures, Mr Ulmer will be a significant asset to the Aravax Board of Directors.” Aravax CEO Dr Pascal Hickey said. “We are delighted to have Mr Ulmer on the board to advise on the direction of all financial matters and work with the team to develop Aravax’s corporate strategy. Mr Ulmer joined the Aravax board at an exciting time in the company following positive phase 1 clinical trial safety results with the phase 2 program on track for next year.” Dr Hickey added.
“I am honoured to be appointed to the Aravax Board of Directors to support the advancement of its important novel treatment,” Mr Ulmer said. “I’m looking forward to working with management and the board on the strategic direction and bright future of the company.”
Mr Ulmer’s global leadership experience spans roles across Europe, USA and Australia. At Immatics N.V. Mr. Ulmer was instrumental in leading the company through its successful NASDAQ-listing in 2020. Prior to this, Mr Ulmer held the position of CFO to Allergopharma, a medium-sized European allergy company. Furthermore, he held various leadership positions within the Merck Group such as Global Head of Business Planning & Analysis, Chief Financial Officer for Australia/ New Zealand and Financial Controller for Merck’s generics business. Mr. Ulmer is a Fellow of CPA Australia (FCPA) and holds an MBA.
ENDS
About Aravax
Aravax is a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The treatment uses highly targeted technology that can reset the immune system to tolerate peanut without evoking allergic reactions during treatment.
Aravax’s technology is underpinned by over a decade of research led by Professor Robyn O’Hehir and her team at Alfred Health and Monash University, which has been supported by the Australian Food Allergy Foundation, the Alfred Hospital Trust, and the National Health and Medical Research Council of Australia.
Aravax developed PVX108 by carefully selecting fragments (peptides) of peanut proteins to switch off allergic reactions to peanuts. The product does not contain whole protein allergens, which are known to cause life-threatening anaphylactic reactions. PVX108 therefore has the potential to break the paradigm of allergen immunotherapy by targeting the underlying cause of disease without exposing patients to the risk of acute reactions to treatment.
Aravax is headquartered in Melbourne, Australia.
For more information visit: www.aravax.com.au
